Chung-Fan (Joseph) Kuo, PhD
Originally from Taiwan, Chung-Fan (Joseph) Kuo received his Master’s degree of Bioengineering at Penn State University in 2014 and his PhD degree in 2022 from the University of Houston. He joined the lab in October 2022 after his PhD graduation. Between his Master and PhD study, he also worked in a clinical cancer research company, Caris Life Sciences, as a Research Associate, supporting the development of advanced cancer diagnosis systems.
Joseph has more than eight years of experience in nanomedicine delivery, primarily in the field of cancer in preclinical setting. His research focuses on developing state-of-the-art nanomedicines for the treatment of different types of brain cancers. His profession of nanoparticle formulations includes applying physiochemistry and organic chemistry to formulate liposomes, polymeric nanoparticles, hybrid nanoparticles, and cyclodextrin-based nanoparticles. These formulations are engineered to improve delivery of cancer therapeutics for the applications of human glioblastoma and medulloblastoma. His current research plan as a Post-Doctoral at UMass Chan Medical School is to develop targeting nanomedicine for human medulloblastoma to improve its overall efficacy. Several in vitro and in vivo evaluations will be carried out to determine nanomedicine’s pharmacokinetics and pharmacodynamics. The long-term outcome of this work will be the development of new clinical trials for pediatric brain cancers.